ReviewMolecular biology reports2026
Glioblastoma exosomes reprogramming the tumor microenvironment and evading therapeutic challenges.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimized Wound Healing Assay to Study Extracellular Vesicle-Driven Glioblastoma Cell Migration.Methods and protocols · 2026Article
- Glioma-derived extracellular vesicles as drivers of immunotherapeutic resistance: mechanisms of immune reprogramming and metabolic intervention.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Glioblastoma (GBM) leverages exosomes to drive tumor progression, immunosuppression, and therapy resistance through transfer of oncogenic miRNAs, circRNAs, and proteins. These vesicles reprogram the tumor microenvironment (TME) by activating pathways such as TREM1 in microglia and STAT3-mediated vasculogenic mimicry. Exosomal nucleic acids, including circZNF800 and miR-374b-3p, serve as non-invasive biomarkers for recurrence and treatment monitoring. Advances in engineering, such as Angiopep-2-functionalized exosomes for blood-brain barrier penetration and CRISPR-Cas9-loaded vesicles targeting resistance genes, highlight their therapeutic potential. Challenges in heterogeneity, standardization, and scalable production underscore the need for interdisciplinary innovation to translate exosome-based strategies into clinical practice.
Indexed as
Identifiers
41712115What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.